159 related articles for article (PubMed ID: 30560089)
1. Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients.
Johansson J; Kiffin R; Andersson A; Lindnér P; Naredi PL; Olofsson Bagge R; Martner A
Front Oncol; 2018; 8():570. PubMed ID: 30560089
[TBL] [Abstract][Full Text] [Related]
2. Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis.
Johansson J; Kiffin R; Aydin E; Nilsson MS; Hellstrand K; Lindnér P; Naredi P; Olofsson Bagge R; Martner A
Oncoimmunology; 2020; 9(1):1684126. PubMed ID: 32002296
[TBL] [Abstract][Full Text] [Related]
3. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
[TBL] [Abstract][Full Text] [Related]
4. Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma.
Olofsson R; Lindberg E; Karlsson-Parra A; Lindnér P; Mattsson J; Andersson B
Int J Hyperthermia; 2013 May; 29(3):234-8. PubMed ID: 23590363
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs.
Thompson JF; Gianoutsos MP
World J Surg; 1992; 16(2):227-33. PubMed ID: 1561803
[TBL] [Abstract][Full Text] [Related]
6. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
Hoekstra HJ; Veerman K; van Ginkel RJ
J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
[TBL] [Abstract][Full Text] [Related]
7. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
[TBL] [Abstract][Full Text] [Related]
8. Acidosis plus melphalan induces nitric oxide-mediated tumor regression in an isolated limb perfusion human melanoma xenograft model.
Kelley ST; Menon C; Buerk DG; Bauer TW; Fraker DL
Surgery; 2002 Aug; 132(2):252-8. PubMed ID: 12219020
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma.
Kiffin R; Johansson J; Olofsson Bagge R; Martner A
Eur J Surg Oncol; 2021 Sep; 47(9):2460-2464. PubMed ID: 33980416
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb.
Noorda EM; Vrouenraets BC; Nieweg OE; Klaase JM; van der Zee J; Kroon BB
Melanoma Res; 2003 Aug; 13(4):395-9. PubMed ID: 12883366
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A
In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425
[TBL] [Abstract][Full Text] [Related]
12. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
13. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
[TBL] [Abstract][Full Text] [Related]
14. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
Liénard D; Eggermont AM; Koops HS; Kroon B; Towse G; Hiemstra S; Schmitz P; Clarke J; Steinmann G; Rosenkaimer F; Lejeune FJ
Melanoma Res; 1999 Oct; 9(5):491-502. PubMed ID: 10596916
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
16. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
17. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
18. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
19. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
20. Isolated limb perfusion in primary and recurrent melanoma: indications and results.
Liénard D; Eggermont AM; Kroon BB; Schraffordt Koops H; Lejeune FJ
Semin Surg Oncol; 1998; 14(3):202-9. PubMed ID: 9548602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
